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Abstract
Background: Vitamin D deficiency is associated with a range of systemic diseases including ocular disorders. The
objective of this study is to measure tear vitamin D levels and investigate the correlation between serum and tear
vitamin D levels.
Methods: A total of 48 healthy volunteers without any systemic and ocular disease were recruited for this
observational cohort study. Serum was collected using clot activator coated Vacutainer® Plus tubes. Tear fluid was
collected using Schirmer’s strips. Serum and tear total 25-hydroxyvitamin D levels were measured by competitive
chemiluminescent ELISA and the correlation between the levels were studied.
Results: The measured serum 25-hydroxyvitamin D level ranged between 3.3 and 27.5 ng/ml (Mean ± SEM, 9.4 ± 0.
7 ng/ml; Median 8.4 ng/ml). Significantly (p < 0.0001) higher level of 25-hydroxyvitamin D was detected in the tears
(Mean ± SEM, 17.0 ± 1.6 ng/ml; Range 3.2–45.8 ng/ml; Median, 16.3 ng/ml) compared to serum. An average of ~2
fold (Mean ± SEM, 1.9 ± 0.2; Range 0.4–5.8; Median, 1.7) higher 25-hydroxyvitamin D was observed in tears
compared to serum in the subjects. In addition, a positive correlation was observed between serum and tear 25-
hydroxyvitamin D levels (r = 0.5595; p < 0.0001).
Conclusions: A higher level of 25-hydroxyvitamin D was observed in the tear fluid compared to that of the serum.
It would be beneficial to consider tear vitamin D levels to study its role with reference to ocular surface diseases.
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Précis
25-hydroxyvitamin D measured in the tear fluid was




Vitamin D is well known for regulating calcium homeo-
stasis, immune response, cellular proliferation and differ-
entiation, angiogenesis, apoptosis and nociception [1, 2].
A high prevalence of vitamin D deficiency has been doc-
umented worldwide [1]. The optimal vitamin D (total
25-hydroxyvitamin D) level ranges between 30 and
80 ng/ml in the serum, and deficiency/insufficiency of
vitamin D is considered when total 25-hydroxyvitamin D
is <20 ng/ml [3, 4]. Owing to its pleiotropic nature and
ubiquitous expression of vitamin D receptor (VDR) in
almost all cells and tissues [5], deficiency of vitamin D
has been associated with a range of diseases, and supple-
mentation of vitamin D has substantially improved the
prognosis of these diseases [6]. Vitamin D status in the
serum is suitable for studying its association with sys-
temic conditions. However, it would be beneficial to
obtain tissue specific vitamin D status for localized con-
ditions such as ocular surface disease. There is increas-
ing evidence regarding extra-renal synthesis and tissue-
specific effects of vitamin D3 in other tissues [7], includ-
ing, the eye [8–11]. The cells and tissues in the eye are
responsive to 1,25-dihydroxyvitamin D since VDR is
present in the epithelium of the cornea, lens and ciliary
body, corneal endothelium, retinal pigment epithelium,
ganglion cell layer and photoreceptors of the human eye
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[8, 12]. Hence, vitamin D status is being associated with
the incidence and severity of various ocular conditions,
including myopia, age-related macular degeneration,
diabetic retinopathy and uveitis [10]. Serum 25-
hydroxyvitamin D levels were also reported to be as-
sociated with some ocular surface conditions such as
dry eye and allergic conjunctivitis [13–15]. In vivo
reports provide evidence concerning the anti-
inflammatory and immunomodulatory roles of vita-
min D in the corneal region [16, 17]. The role of
vitamin D in ocular surface conditions, mechanistic
insights into the aetiopathology of vitamin D defi-
ciency and beneficial effects of vitamin D supple-
mentation in the management of ocular surface
conditions are yet to be studied. Determining local
vitamin D levels in the eye is essential to meet this
knowledge gap. Therefore, the current study aims to
quantify 25-hydroxyvitamin D in tear fluid and cor-
relate its level with that in the serum.
Methods
Study design & clinical examination
The observational cohort study approved by the Nar-
ayana Nethralaya Institutional Review Board (Ref. No.:
C/2015/05/05) was conducted in adherence to Indian
Council for Medical Research (ICMR) guidelines and
tenets of the Declaration of Helsinki. A total of 48
healthy volunteers were selected (after obtaining in-
formed written consent) for the study after thorough
clinical investigation at Narayana Nethralaya Eye Hos-
pital, Bangalore, India to rule out any ongoing or recent
ocular and/or systemic co-morbidity. In addition, con-
tact lens wearers were not included in the study.
Serum and tear sample collection
Serum was isolated by centrifuging peripheral venous
blood collected in BD Vacutainer® Plus Plastic Serum
Tubes (BD, New Jersey, USA) with spray-coated silica
as a clot activator and stored in −80 °C until further
use. Tear fluid from the subjects were collected using
sterile Schirmer’s strip (5 × 35-mm2; Tear Strips, Con-
tacareOpthalmics and Diagnostics, India) by following
Schirmer’s Test I procedure and stored at -80 °C in a
sterile microcentrifuge tube until further use. Tear
fluid was extracted from Schirmer’s strips by agitating
small cut pieces of these strips in phosphate buffered
saline (PBS) solution in a sterile microcentrifuge tube
at +4 °C for 1.5 h. Tear fluid was then eluted by cen-
trifugation and stored at −80 °C until further use.
Schirmer’s strip based tear fluid collection was
followed as it was reported to be suitable and com-
parable with capillary tube based tear fluid collection
for downstream analysis [18].
Measurement of serum and tear vitamin D
Total 25-hydroxyvitamin D (25-hydroxyvitamin D3 + 25-
hydroxyvitamin D2) levels in the serum and tear fluid
were measured by direct competitive chemiluminescent
enzyme linked immunoassay – 25-hydroxyvitamin D
ELISA Kit (Enzo Life Sciences, Switzerland). The kit was
optimized and validated to detect serum vitamin D. As
assays to detect tear 25-hydroxyvitamin D are unavail-
able, we adapted the above mentioned kit to quantify
tear 25-hydroxyvitamin D. Since the tear fluid was
eluted in PBS, we included additional PBS based 25-
hydroxyvitamin D3 (Cayman Chemical, Ann Arbor,
MI, USA) standards for the assays. 25-hydroxyvitamin
D3 is the most predominant and endogenous form of
vitamin D which is the major contributor towards
measured total vitamin D - 25-hydroxyvitamin D levels.
The accuracy of this modified assay results was evaluated
by comparing results from an automated direct competi-
tive chemiluminescent enzyme linked immunoassay
(ADVIA Centaur® Vitamin D Total, Siemens) that detects
both 25-hydroxyvitamin vitamins D2 and D3. The latter
was chosen to validate our method because it was
reported to have acceptable accuracy compared with LC-
MS/MS [19]. Furthermore, the levels of tear 25-
hydroxyvitamin D were normalized to the amount of tear
fluid collected for the measurements.
Statistical analysis
All statistical analyses were performed with GraphPad
Prism 6.0 (GraphPad Software, Inc., La Jolla, CA, USA)
and Stata 12.1 (StataCorp, Texas USA). Shapiro-Wilk
normality test was used to check the distribution of the
data set. Spearman correlations analysis, Wilcoxon
matched-pairs signed rank test and Mann-Whitney test
were used to analyse data sets that were not normally
distributed. The agreement between the data sets was
analysed using the Bland-Altman plot. The mean or
median value of the individual groups was reported
as Mean ± SEM or median (along with the range).
Two-tailed p < 0.05 was considered to be statistically
significant.
Results
The study cohort included 21 male and 27 female sub-
jects of Indian origin. The age of subjects in the cohort
ranged from 19 to 53 years (Mean ± SEM, 31 ± 1.1 years;
Median 28.5 years). To evaluate the validity of our modi-
fied method in estimating total 25-hydroxyvitamin D in
serum and tears, the levels of 25-hydroxyvitamin D in
serum were measured in 36 samples using modified
method and automated immunoassay. A significant
positive correlation (r = 0.6391, Spearman correlation;
p < 0.0001; n = 36) was observed between the two
methods (Fig. 1a). The Bland-Altman plot evaluating
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Fig. 1 Comparative analysis of serum 25-hydroxyvitamin D measurement protocols. a Graph shows the correlation of serum total 25-hydroxyvitamin
D [25(OH) Vit D] levels measured by manual direct competitive chemiluminescent enzyme linked immunoassay with PBS-based 25-hydroxyvitamin D3
standards; current method (y axis) and automated direct competitive chemiluminescent enzyme linked immunoassay (x axis). r - Spearman correlation;
n = 36. b Bland-Altman plot showing the agreement between the two methods used to measure serum 25-hydroxyvitamin D. The average total 25-
hydroxyvitamin D in the x-axis indicates the mean of serum 25-hydroxyvitamin D level measured by the current method using PBS-based
25-hydroxyvitamin D3 standards and by automated immunoassay
Fig. 2 Correlative evaluation of total 25-hydroxyvitamin D levels in serum and tear fluid. a Box and whiskers plot indicating the median levels of
total 25-hydroxyvitamin D measured in the serum and tear fluid. b Correlation between serum and tear total 25-hydroxyvitamin D [25(OH) Vit D]
levels (n = 48), r - Spearman correlation. c Bland-Altman plot showing the agreement between tear and serum 25-hydroxyvitamin D levels. The
average total 25-hydroxyvitamin D in the x-axis indicates the mean of tear and serum 25-hydroxyvitamin D levels. n = 48; ****p < 0.0001, Wilcoxon
matched-pairs signed rank test
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the agreement between serum 25-hydroxyvitamin D
levels measured by these methods showed that 95 %
limits of agreement were between -5.8 and 11.4 ng/ml
(Fig. 1b). These observations support the applicability of
the modified method in measuring 25-hydroxyvitamin D
in both serum and tears.
The measured serum 25-hydroxyvitamin D level in 48
subjects ranged between 3.3 and 27.5 ng/ml (Mean ±
SEM, 9.4 ± 0.7 ng/ml; Median, 8.4 ng/ml). A total of
64.6 % (31/48) of the study cohort had serum 25-
hydroxyvitamin D <10 ng/ml (severe deficiency), 31.3 %
(15/48) had serum 25-hydroxyvitamin D between 11 and
20 ng/ml (moderate deficiency) and 4.2 % (2/48) was
between 21 and 30 ng/ml (vitamin D insufficiency). No
significant difference was observed in the serum 25-
hydroxyvitamin D level between male (Mean ± SEM, 9.1 ±
0.8 ng/ml; Median, 9.3 ng/ml) and female (Mean ± SEM,
9.7 ± 1.1 ng/ml; Median, 7.6 ng/ml) subjects in the
study cohort. The tear 25-hydroxyvitamin D level was
17.0 ± 1.6 ng/ml (Mean ± SEM) with values ranging
between 3.2 and 45.8 ng/ml (Median, 16.3 ng/ml).
Similar to serum 25-hydroxyvitamin D, significant
difference was not observed in the tear 25-
hydroxyvitamin D level between male (Mean ± SEM,
15.7 ± 2.5 ng/ml; Median, 13.4 ng/ml) and female
(Mean ± SEM, 18.1 ± 2.2 ng/ml; Median, 1.8 ng/ml)
subjects in the study cohort. However, a significantly
(p < 0.0001) higher tear 25-hydroxyvitamin D compared to
matched serum 25-hydroxyvitamin D levels was observed
(Fig. 2a). Post-hoc calculation determined that the power
of detection was greater than 80 % and hence the sample
size was adequate for the observation made. 35.4 % (17/
48) of subjects had tear 25-hydroxyvitamin D <10 ng/ml,
35.4 % between 11 and 20 ng/ml, 12.5 % (6/48) between
21 and 29 ng/ml and 16.6 % (8/48) with >30 ng/ml. A
significant positive correlation (r = 0.5595, Spearman
correlation; p < 0.0001) was also observed between tear
and serum 25-hydroxyvitamin D (Fig. 2b). The Bland-
Altman plot evaluating the agreement between tear and
serum 25-hydroxyvitamin D levels shows 95 % limits of
agreement were between -10.78 and 26.06 ng/ml (Fig. 2c).
Tear 25-hydroxyvitamin D levels were higher than serum
in the majority of the subjects. It was found to be 1.9 ± 0.2
(Mean ± SEM) fold higher than the serum 25-
hydroxyvitamin D levels when quantified in the
current modified method. The fold difference ranged
between 0.4 and 5.8 (Median, 1.7). In 16.7 % (8/48)
of subjects the tear 25-hydroxyvitamin D was lower
than that of its matched serum levels and in 83.3 %
(40/48) of samples the tear 25-hydroxyvitamin D was
either equal or higher than that measured in the re-
spective matched serum. Among the samples in
which the tear 25-hydroxyvitamin D was either equal
or higher than serum, in 20 % (8/40) the difference
was within 2 ng/ml, in 45 % (18/40) the difference
was >2 but ≤10 ng/ml, in 25 % (10/40) the differ-
ence ranged between 10 and 20 ng/ml and in 10 %
(4/40) the difference was between 21 and 37.5 ng/
ml. The current observations suggest that tear fluid
may have a higher level of 25-hydroxyvitamin D
compared with serum.
Discussion
Serum vitamin D deficiency is associated with various
systemic conditions and recently its relevance in ocular
health and disease is being reported [10]. There is grow-
ing evidence regarding 25-hydroxyvitamin D status in
ocular surface diseases such as allergic conjunctivitis and
dry eye [13, 14, 20]. However, there has been some
rather contradicting observations with regards to 25-
hydroxyvitamin D and dry eye [15, 21]. Nevertheless,
all these reports have been based on serum 25-
hydroxyvitamin D. We suggest that assessing 25-
hydroxyvitamin D status in tears would hold more
relevance in eye disease, especially in ocular surface
conditions. Vitamin D (both 25-hydroxyvitamin D3
and 1,25-dihydroxyvitamin D3) was shown to influ-
ence corneal epithelial barrier function by regulating
expression of occludin [11], and the ability of corneal
epithelial cells to synthesize and metabolize vitamin D
has also been documented [8, 9]. An in vivo study in
rabbits showed that 25-hydroxyvitamin D can be mea-
sured in tears and its level increases in the tears following
oral supplementation of vitamin D [9]. In the current
study, we have shown that 25-hydroxyvitamin D can be
measured in human tears by competitive chemilumines-
cent immunoassay and that the 25-hydroxyvitamin D
levels were significantly higher in the tears than in the
serum. Similarly, another study reported significantly
higher 25-hydroxyvitamin D levels in tears (71.8 ± 6.2 ng/
ml) compared to serum (21.8 ± 11.3 ng/ml) in children
(12.5 ± 2.5 years) using electro chemiluminescent im-
munoassay [22]. The difference in the 25-hydroxyvitamin
D levels between tear fluid and serum seem to vary be-
tween the current study and that reported by Goksugur
SB et al. The primary reason underlying this difference
could be related to the principle and sensitivity of the
assay used to measure 25-hydroxyvitamin D [23, 24].
Moreover, we have modified the method to render more
accurate measurement of 25-hydroxyvitamin D in tear
fluid. The age difference between these study cohorts
could also be considered as a possible factor contributing
to the variation. It should also be noted that contrary to
our observation and that of Goksugur SB et al., 25-
hydroxyvitamin D levels in tears was lower than plasma in
rabbits [9], this could once again be attributed to the tech-
nique adopted for quantifying 25-hydroxyvitamin D and
possible inter-species differences. Since the human corneal
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epithelium is capable of synthesizing vitamin D [9], we
speculate that the increased level observed in the tears
could be due to vitamin D produced by the corneal epi-
thelium following exposure of the eye to UVB rays present
in sunlight. Unlike tear fluid, 25-hydroxyvitamin D in the
saliva (another non-invasive source for measuring vitamin
D) was reported to be manifold lower than that of the
serum [25, 26]. Hence, more detailed studies are required
to confirm increased 25-hydroxyvitamin D in tear fluid
and understand the source that contributes to it.
Conclusion
The observations from the current study suggest that
25-hydroxyvitamin D is present in tear fluid and its level
was found to be higher than in the corresponding serum
in humans. It would be beneficial if studies investigating
the association between tear vitamin D and ocular sur-
face disease can determine its relevance with reference
to disease severity and pathogenesis so as to inform the
need for topical supplementation of vitamin D to ameli-
orate ocular surface diseases.
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